Congress Park Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
MSR
PR
SO
WT
AAS
WAM
RFM
NHFG
RAM
Congress Park Capital's XBI Position: Q2 2026 in Review
Congress Park Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.9% in Q2 2026, buying an estimated $21.6K and bringing the position to 5,585 shares worth $884K. The position accounts for 0.24% of the portfolio, ranked #67.
Congress Park Capital first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. 391 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Congress Park Capital held 5,585 shares of State Street SPDR S&P Biotech ETF worth $884K as of Q2 2026.
- Congress Park Capital bought 160 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $21.6K.
- State Street SPDR S&P Biotech ETF made up 0.24% of Congress Park Capital's portfolio in Q2 2026, its #67 holding.
- Congress Park Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
- 391 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.